NNVC Nanoviricides Inc

Price (delayed)

$1.1

Market cap

$12.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

$7.71M

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped ...

Highlights

NNVC's debt has shrunk by 100% QoQ

NNVC's quick ratio has dropped by 78% year-on-year and by 25% since the previous quarter

The equity has declined by 37% year-on-year and by 4% since the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.nanoviricides.com

Peers: BCRX CMRX NVAX GILD

Key stats

What are the main financial stats of NNVC

Market

Shares outstanding

11.78M

Market cap

$12.96M

Enterprise value

$7.71M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

1.04

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$9.31M

EBITDA

-$8.55M

Free cash flow

-$6.2M

Per share

EPS

-$0.81

Free cash flow per share

-$0.53

Book value per share

$1.06

Revenue per share

TBVPS

$1.11

Balance sheet

Total assets

$13.4M

Total liabilities

$951,074

Debt

Equity

$12.45M

Working capital

$4.37M

Liquidity

Debt to equity

Current ratio

5.59

Quick ratio

5.52

Net debt/EBITDA

0.61

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-58.2%

Return on equity

-64%

Return on invested capital

-117.8%

Return on capital employed

-74.7%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

NNVC stock price

How has the Nanoviricides stock price performed over time

Intraday

-6.78%

1 week

-12%

1 month

-4.35%

1 year

-20.67%

YTD

7.84%

QTD

-5.17%

Financial performance

How have Nanoviricides's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$9.7M

Net income

-$9.36M

Gross margin

N/A

Net margin

N/A

Nanoviricides's operating income has decreased by 38% YoY and by 3.8% QoQ

NNVC's net income is down by 36% YoY and by 4.1% QoQ

Growth

What is Nanoviricides's growth rate over time

Valuation

What is Nanoviricides stock price valuation

P/E

N/A

P/B

1.04

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

The EPS has contracted by 35% YoY and by 3.8% from the previous quarter

The equity has declined by 37% year-on-year and by 4% since the previous quarter

The stock's price to book (P/B) is 26% less than its 5-year quarterly average of 1.4 but 4% more than its last 4 quarters average of 1.0

Efficiency

How efficient is Nanoviricides business performance

Nanoviricides's return on equity has shrunk by 107% YoY and by 17% QoQ

NNVC's return on assets has dropped by 92% year-on-year and by 15% since the previous quarter

Nanoviricides's return on invested capital has decreased by 46% YoY and by 8% QoQ

Dividends

What is NNVC's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for NNVC.

Financial health

How did Nanoviricides financials performed over time

NNVC's total liabilities has soared by 105% YoY but it has shrunk by 61% QoQ

The current ratio has shrunk by 78% YoY and by 26% QoQ

NNVC's debt is 100% lower than its equity

NNVC's debt has shrunk by 100% QoQ

NNVC's debt to equity has dropped by 100% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.